Nano-scale medicines, sensors, implants and imaging modalities have the potential to revolutionise health care. The global nanomedicine market was reported to be worth $72.8 billion by 2011, $138 billion in 2016 and is predicted to be worth $350 billion by 2025 .
The scientists and entrepreneurs who survive and prosper amidst such remarkable impact and growth are those who have the best comprehension of the pathway to market. Ensuring your innovative nanotechnologies have the optimal opportunity to fulfil their potential requires an understanding of the regulatory, financial, clinical and commercial challenges faced. The Clinical Translation and Commercialisation of Nanomedicine course aims to provide this understanding. The course will encourage students and researchers to think about the entire pathway of testing and commercialising their scientific ideas, and to introduce them to issues surrounding regulation, intellectual property and financing. Lecturers with expertise and experience in each of these key spheres will provide important insights, whilst case-studies will be lead by entrepreneur scientists who have successfully navigated the pathway.
The Clinical Translation and Commercialisation of Nanomedicine course can be taken alone, with or without academic credit, or as part of the MSc in Nanotechnology for Medicine and Health Care.
The Clinical Translation and Commercialisation of Nanomedicine course will provide students with the opportunity to gain knowledge and understanding of:
- The pre-clinical, clinical and regulatory pathways required for approval
- Market and intellectual property assessment
- Mechanisms and sources of finance
- Notable case studies